Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
/ 4 items
#NUVB↓
Clear Street Maintains Buy on Nuvation Bio Despite Pipeline Adjustment
Clear Street keeps $12 price target on NUVB after NUV-1511 discontinuation, citing blockbuster potential for IBTROZI and safusidenib programs.
Nuvation Bio Soars on Ibtrozi Success and Analyst Upgrades
Nuvation Bio shares jump 49% Wed. after strong Ibtrozi results and analyst upgrades, signaling growth potential in biotech and cancer treatments.
Major Buy Signal! Jefferies Initiates Coverage on Nuvation Bio
Jefferies issued a Buy rating on Nuvation Bio with a $10 price target, citing its FDA-approved lead drug, strong pipeline potential, and cash reserves extending into 2028.